Full-Time

Scientific Partnership Medical Director

Updated on 7/21/2026

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

$299.8k - $369.8k/yr

+ Annual Bonus Plan + Incentive Compensation Plan + Discretionary Equity Awards + Employee Stock Purchase Plan

United States

Hybrid

Remote within the United States with approximately 50% travel; must reside within the assigned geographic region.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Sharepoint
Communications
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to BeOne

Find people who can refer or advise you

Requirements
  • Advanced degree (MD, PharmD, PhD, or DO) required within a clinical and/or scientific profession
  • MD, PharmD, PhD, or DO with 10+ years of experience in the pharmaceutical or biopharmaceutical industry required
  • Medical Affairs experience required, including field-based or account-facing medical roles
  • Deep knowledge of the US clinical oncology landscape, including health systems, oncology networks, and IDN structures
  • Established peer-level relationships with Institutional Leaders, Key Opinion Leaders (KOLs) and Key Decision Makers (KDMs), including oncology clinical and research thought leaders and access-related experts
  • Broad oncology expertise across multiple tumor types and therapeutic platforms
  • Ability to travel within assigned geographic region; candidate must reside within the assigned territory
  • PC literacy required; MS Office skills (Outlook, Word, Excel, PowerPoint, SharePoint)
  • Working knowledge of US healthcare landscape, regulatory requirements, and compliance standards
  • Capabilities: Impactful verbal and written communication skills; Ability to effectively collaborate and lead through influence in a dynamic matrix environment; Strong disease state comprehension, breadth of oncology knowledge across tumor types, and experience in therapeutic areas of interest to BeOne Medicines; Expert understanding of the US healthcare delivery system, managed care, and enterprise health system structures; Ability to identify unmet medical, educational, and research needs at the institutional and regional level; Ability to interpret key scientific data and translate findings to support evidence generation and research strategy; Understanding of research study design, execution, and strategic implications; High emotional intelligence and appreciation of diversity and multiculturalism; Strategic and creative thinker with proven ability to drive high-quality results; Ability to deal with ambiguity and thrive in an ever-changing environment; Effective project management and leadership skills; Strong time management and organizational skills
Responsibilities
  • Serve as the primary medical interface and single point of scientific contact for C-suite and D-suite leadership at priority US health systems and oncology networks within the assigned geographic territory
  • Develop, maintain, and execute a clear enterprise-level medical account strategy plan that reflects NAMA, R&D, and Franchise/Commercial Leadership priorities for each assigned health system
  • Engage health system leaders holistically, addressing system-wide scientific and clinical priorities rather than isolated, product-specific needs
  • Champion innovative scientific engagement opportunities including clinical trial placement, investigator-initiated research, and evidence generation programs tailored to each system’s strategic priorities
  • Orchestrate and coordinate BeOne Medicines’ medical and scientific resources — including FMDs, RMSLs, HOM, GMA, HEOR/RWE, and Clinical Operations — to comprehensively address the scientific and evidence needs of decision-makers at assigned health systems
  • Develop and drive scientific information exchanges, data presentations, and evidence-based dialogues with institutional medical and scientific leaders
  • Coordinate BeOne Medicines’ full oncology portfolio representation across tumor types and therapeutic platforms, with emphasis on engagement early in the development process
  • Lead through influence across BeOne Medicines’ internal matrix partners — including FMDs, RMSLs, HOM, GMA, HEOR/RWE, R&D, Market Access, Clinical Operations, and Franchise/Commercial Leadership — to deliver coordinated enterprise solutions at assigned health systems
  • Build and sustain strong medical relationships across BeOne Medicines functions and with key scientific decision-makers at priority institutions
  • Communicate account-level insights, scientific trends, and institutional priorities back to NAMA leadership to inform strategy and resource decisions
  • Develop and implement integrated account strategies synchronized with NAMA, R&D, Market Access, Clinical Operations, and Franchise/Commercial Leadership objectives
  • Support change management efforts embedding new scientific engagement strategies across internal and external stakeholders
  • Attend and represent BeOne Medicines at key national and regional oncology congresses, advisory boards, and health system scientific forums
  • Be accountable for compliant business practices in all field activities
Desired Qualifications
  • Broader enterprise experience across multiple functional areas beyond Medical Affairs is a plus

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sonrotoclax received US FDA accelerated approval in May 2026 with 52% ORR and 15.8-month median duration
  • Brukinsa generated $1.1B in Q1 2026 sales, up 38%, anchoring 73% of total quarterly revenue
  • HER2 regimen for gastric cancer got FDA Breakthrough Therapy in June 2026 with Phase 3 survival benefits

What critics are saying

  • Brukinsa revenue may collapse within 12-18 months as ibrutinib gains generic adoption post-2025 patent invalidation
  • Sonrotoclax risks FDA withdrawal in 18-24 months if CELESTIAL-RRMCL Phase 3 fails to confirm 52% ORR
  • ZIIHERA may face 20-30% price compression and slow adoption due to trastuzumab's 80% gastric cancer market share

What makes BeOne unique

  • Sonrotoclax is the first BCL2 inhibitor approved for relapsed/refractory mantle cell lymphoma in the US
  • Brukinsa is the only BTK inhibitor showing superiority over ibrutinib in frontline CLL head-to-head trials
  • BeOne runs the only fixed-duration BCL2+BTK combo trial designed to prove superiority in treatment-naïve CLL/SLL

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

-20%

1 year growth

-24%

2 year growth

-17%
Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Feb 26th, 2026
BeOne Medicines reports $1.5B revenue, up 33% despite EPS miss in Q4

BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.

Business Wire
Feb 26th, 2026
BeOne Medicines reports $5.3B full-year revenue as BRUKINSA sales surge 49%

BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.

Yahoo Finance
Feb 2nd, 2026
BeOne Medicines trades at $340 with 51% annual return amid undervaluation signals

BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.

TipRanks
Nov 20th, 2025
BeOne Medicines Secures $1 Billion Financing Agreement - TipRanks.com

BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...